URGN insider transactions
UroGen Pharma Ltd. (URGN) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for URGN
- Director Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 100% to 4,000 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- General Counsel Smith Jason Drew converted options into 15,500 units of Ordinary Shares and sold $147,262 worth of Ordinary Shares (7,479 units at $19.69), increasing direct ownership by 11% to 55,588 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark sold $145,174 worth of Ordinary Shares (7,373 units at $19.69), decreasing direct ownership by 5% to 144,985 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 13,333 units of Ordinary Shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Degnan Chris4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Director Holden Stuart converted options into 2,000 units of ordinary shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Director Butitta Cynthia M converted options into 2,000 units of ordinary shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Director Robinson James A. Jr. converted options into 2,000 units of ordinary shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Director Wen Leana converted options into 2,000 units of ordinary shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Director Wildman Daniel George converted options into 2,000 units of ordinary shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark sold $250,000 worth of Ordinary Shares (10,000 units at $25.00), decreasing direct ownership by 7% to 139,025 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Financial Officer Degnan Chris converted options into 4,483 units of Ordinary Shares and sold $37,121 worth of Ordinary Shares (2,203 units at $16.85) (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 1,667 units of Ordinary Shares and sold $16,645 worth of Ordinary Shares (871 units at $19.11), increasing direct ownership by 0.54% to 149,025 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- General Counsel Smith Jason Drew sold $29,047 worth of Ordinary Shares (1,520 units at $19.11) and converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 4% to 43,305 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Wildman Daniel George4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Robinson James A. Jr.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Holden Stuart4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Butitta Cynthia M4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Wen Leana4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Belldegrun Arie4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark sold $176,900 worth of Ordinary Shares (10,000 units at $17.69), decreasing direct ownership by 6% to 148,229 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- General Counsel Smith Jason Drew sold $143,971 worth of Ordinary Shares (7,522 units at $19.14) and converted options into 16,500 units of Ordinary Shares, increasing direct ownership by 28% to 41,492 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $98,552 worth of Ordinary Shares (5,149 units at $19.14), increasing direct ownership by 3% to 158,229 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $38,044 worth of Ordinary Shares (5,162 units at $7.37), increasing direct ownership by 3% to 153,378 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 8,000 units of Ordinary Shares and sold $50,698 worth of Ordinary Shares (4,551 units at $11.14), increasing direct ownership by 2% to 148,540 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- General Counsel Smith Jason Drew converted options into 14,667 units of Ordinary Shares and sold $82,202 worth of Ordinary Shares (7,379 units at $11.14), increasing direct ownership by 29% to 32,514 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Degnan Chris4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 3 filed by new insider Degnan Chris3 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 1,666 units of Ordinary Shares and sold $11,236 worth of Ordinary Shares (859 units at $13.08), increasing direct ownership by 0.56% to 145,091 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- General Counsel Smith Jason Drew sold $19,895 worth of Ordinary Shares (1,521 units at $13.08) and converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 8% to 25,226 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Financial Officer Kim Dong converted options into 2,500 units of Ordinary Shares, increasing direct ownership by 7% to 37,753 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Belldegrun Arie4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Cohen Fred E4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Wildman Daniel George4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Holden Stuart4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Robinson James A. Jr.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Wen Leana4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Director Butitta Cynthia M4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $67,401 worth of Ordinary Shares (5,153 units at $13.08), increasing direct ownership by 3% to 144,284 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Schoenberg Mark sold $168,600 worth of Ordinary Shares (12,000 units at $14.05), decreasing direct ownership by 8% to 139,437 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Kim Dong converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 10% to 35,253 units (SEC Form 4) (Amendment)4/A - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Kim Dong (Amendment)4/A - UroGen Pharma Ltd. (0001668243) (Issuer)
- Smith Jason Drew sold $78,790 worth of Ordinary Shares (4,993 units at $15.78), increasing direct ownership by 22% to 23,414 units (SEC Form 4) (Amendment)4/A - UroGen Pharma Ltd. (0001668243) (Issuer)
- Schoenberg Mark sold $59,790 worth of Ordinary Shares (3,789 units at $15.78), increasing direct ownership by 0.58% to 151,437 units (SEC Form 4) (Amendment)4/A - UroGen Pharma Ltd. (0001668243) (Issuer)
- Smith Jason Drew sold $78,590 worth of Ordinary Shares (4,993 units at $15.74) and converted options into 10,000 units of Ordinary Shares, increasing direct ownership by 27% to 23,414 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Schoenberg Mark converted options into 6,666 units of Ordinary Shares and sold $59,639 worth of Ordinary Shares (3,789 units at $15.74), increasing direct ownership by 2% to 151,437 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- Kim Dong converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 14% to 26,585 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Barrett Elizabeth A.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Belldegrun Arie4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Butitta Cynthia M4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Cohen Fred E4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Wildman Daniel George4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Holden Stuart4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Robinson James A. Jr.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Wen Leana4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Smith Jason Drew4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SEC Form 4 filed by Kim Dong4 - UroGen Pharma Ltd. (0001668243) (Issuer)